SXTP

60 Degrees Pharmaceuticals, Inc. NASDAQ Listed Jul 12, 2023

Healthcare ·Biotechnology ·US · 60degreespharma.com

$1.58

Mkt Cap $1.3M

52w Low $1.29 2.2% of range 52w High $14.68

50d MA $1.97 200d MA $3.93

P/E (TTM) -0.1x

EV/EBITDA -0.0x

P/B 0.3x

Debt/Equity 0.0x

ROE —

P/FCF -0.2x

RSI (14) —

ATR (14) —

Beta 3.28

50d MA $1.97

200d MA $3.93

Avg Volume 1.3M

60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. It offers Arakoda for malaria preventative treatment. The company also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for Zika, respiratory viruses, and dengue. It also has patent license agreement with Tufts Medical Center to jointly advance the development and commercialization of tafenoquine for the treatment and prevention of babesiosis. The company was founded in 2010 and is headquartered in Washington, District Of Columbia.

CIK (SEC)

1946563

Phone

202 327 5422

1025 Connecticut Avenue NW · Washington, DC 20036 · US

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
Mar 26, 2026	AMC	-2.28	-1.91	+16.2%	1.49	-2.0%	+0.7%	+0.7%	+15.9%	+6.9%	-0.5%	—
Nov 13, 2025	AMC	-1.84	-2.64	-43.5%	4.68	-1.7%	-22.2%	+12.1%	+1.0%	+1.9%	-3.8%	—
Aug 13, 2025	AMC	-1.24	-1.25	-0.8%	5.40	-2.2%	-3.0%	+0.8%	-1.5%	-1.5%	-0.8%	—
May 15, 2025	AMC	-1.31	-1.56	-19.1%	8.60	+1.4%	+14.9%	-6.1%	+2.2%	-0.8%	-3.8%	—
Mar 27, 2025	AMC	-4.01	-14.20	-254.1%	7.28	+0.0%	+1.1%	+0.0%	+2.7%	-0.5%	-2.1%	—
Nov 14, 2024	AMC	-3.00	-4.65	-55.0%	19.00	-6.3%	-5.5%	-3.1%	+5.7%	+0.0%	-5.0%	—
Aug 14, 2024	AMC	-19.80	-21.15	-6.8%	26.60	-3.8%	+24.1%	-5.5%	+1.3%	-1.3%	+22.4%	—
May 15, 2024	AMC	-9.60	1.80	+118.8%	51.16	+4.4%	+4.6%	+0.8%	+24.1%	+0.1%	+2.9%	—
Apr 1, 2024	AMC	-16.21	-26.41	-62.9%	65.28	+0.0%	+3.6%	-1.4%	+4.1%	-4.8%	-0.5%	—
Nov 20, 2023	AMC	-15.61	-18.01	-15.4%	152.32	-0.7%	-3.2%	-7.9%	+0.0%	+4.2%	+0.0%	—
Aug 25, 2023	AMC	—	-1.40	—	350.40	+0.7%	-5.5%	+0.7%	+7.0%	-5.9%	+0.6%	—
Mar 31, 2023	AMC	—	-1.87	—	—	—	—	—	—	—	—	—

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Apr 9	Ascendiant Capital	Maintains	Buy → Buy	—	$1.81	$1.81	+0.0%	-3.9%	+1.1%	+10.2%	+14.4%	-11.7%
Jan 27	HC Wainwright & Co.	Maintains	Buy → Buy	—	$4.84	$4.67	-3.5%	-0.4%	+7.9%	-6.9%	-14.3%	-12.3%
Nov 28	Ascendiant Capital	Maintains	Buy → Buy	—	$4.20	$3.92	-6.7%	+1.0%	-2.8%	-3.9%	+3.0%	-3.9%
Sep 3	Ascendiant Capital	Maintains	Buy → Buy	—	$5.68	$5.64	-0.7%	+2.8%	+1.4%	-4.7%	-1.4%	+2.2%
Jun 2	Ascendiant Capital	Maintains	Buy → Buy	—	$10.32	$10.24	-0.8%	+9.3%	+3.2%	-1.7%	+3.5%	-1.4%
Mar 28	HC Wainwright & Co.	Maintains	Neutral → Neutral	—	$7.28	$7.28	+0.0%	+1.1%	+0.0%	+2.7%	-0.5%	-2.1%
Feb 25	HC Wainwright & Co.	Maintains	Neutral → Neutral	—	$8.48	$8.44	-0.5%	-9.4%	+4.7%	-6.5%	-3.7%	-6.1%
Jan 10	HC Wainwright & Co.	Maintains	Neutral → Neutral	—	$21.80	$22.20	+1.8%	-3.7%	-12.4%	+1.1%	-2.6%	-8.8%
Dec 23	HC Wainwright & Co.	Maintains	Neutral → Neutral	—	$25.20	$25.40	+0.8%	-7.9%	+13.8%	+1.5%	-3.7%	-1.6%
Dec 11	HC Wainwright & Co.	Maintains	Neutral → Neutral	—	$39.00	$40.00	+2.6%	+13.3%	-25.3%	-14.5%	+7.1%	-2.0%

Data updated apr 24, 2026 10:38am · Source: massive.com